287121-33-9

Upstream product

• 5874-57-7 R-(-)-serine methyl ester hydrochloride 
• 286459-94-7 4-but-2-ynyloxybenzenesulfonyl chloride 
• 5680-79-5 glycine ethyl ester hydrochloride 

Downstream Products

• 287121-34-0 methyl 2-{(5-fluoro-2-nitrobenzyl)[(4-methoxyphenyl)sulfonyl]amino}-3-hydroxypropanoate 
• 287121-29-3 4-(4-But-2-ynyloxybenzene-sulfonyl)-1-(2-furanylcarbonyl)-2,3,4,5-tetrahydro-1H-[1,4]benzodiazepine-3-carboxylic acid 
• 755889-41-9 1-acetyl-4-(4-but-2-ynyloxy-benzenesulfonyl)-8-hydroxymethyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine-3-carboxylic acid methyl ester 
• 287121-28-2 methyl 1-(2-furanylcarbonyl)-4-(4-but-2-ynyloxybenzenesulfonyl)-2,3,4,5-tetrahydro-1H-[1,4]benzodiazepine-3-carboxylate 

Relevant academic research and scientific papers

2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS

Compounds having formula (1) are useful in treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss.

2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids

Compounds having the following formula: ? are useful in treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss.

Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors

Compounds of the formula: are useful in treating disease conditions mediated by TNF-α, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.